The effect of the GABA-agonist, progabide, on benign essential tremor

Publisher Website
Google Scholar
Abstract
In a double-blind crossover trial of two 2-wk treatment periods, involving 18 patients with benign essential tremor, there was no statistically significant difference between progabide 11.4-20.2 mg/kg .times. day (median 14.2 mg/kg .times. day) and placebo in tremor score and tremor amplitude. There was a definite placebo and period effect with reduction of tremor score and tremor amplitude during the 2nd period of treatment compared to the 1st period of treatment, regardless of the treatment regime. This was presumably a result of prolonged treatment and habituation to the test situation and not an effect of the active drug. No side-effects were registered and no laboratory abnormalities were seen.

This publication has 12 references indexed in Scilit: